DiFusion Technologies is an orthopedics company in Austin, TX focused on the development of CleanFUZE™ antimicrobial technology for use in orthopedic implants. DiFusion has identified several groundbreaking applications for this technology and has laid the framework for its successful commercialization. In fact, preclinical testing showed that CleanFUZE™ can eliminate 99.9999% of active bacterial colonies including Methicillin Resistant Staphylococcus Aureus as well as other virulent bacterial strains often implicated in surgical site infections.

CleanFUZE™ has the potential to deliver benefits across the healthcare spectrum. For patients, it may reduce the risks of additional surgeries and IV or even lifetime suppressive antibiotics. For physicians, CleanFUZE™ utilizes current surgical techniques, well accepted implant designs and current reimbursement codes. Finally, for hospitals and payers, CleanFUZE™ offers potential savings on complications and unreimbursed costs attributable to SSI's.

CleanFUZE™ is under development and not approved for human use by the US FDA.